AstraZeneca reports Q2 core EPS $2.15, consensus $1.97

Reports Q2 revenue $11.42B, consensus $10.96B. Pascal Soriot, CEO, AstraZeneca, said: “Each of our non-COVID-19 therapy areas saw double-digit revenue growth, with eight medicines delivering more than $1B of revenue in the first half, demonstrating the strength of our business. Several medicines grew rapidly including Ultomiris, Imfinzi/Imjudo and Farxiga, with revenues up 64%, 57% and 40% respectively. Our pipeline momentum continues with eight positive pivotal trials for our Oncology medicines so far this year, and we are encouraged by the positive data from TROPION-Lung01, the first pivotal trial of datopotamab deruxtecan. We look forward to sharing the data with the medical community at an upcoming medical congress and are proceeding to file the data with the US Food and Drug Administration. And finally, as part of our flagship sustainability programme, Ambition Zero Carbon, we announced a $400M investment in AZ Forest, raising our commitment to plant 200 million trees by 2030.”